Uveal Melanoma Treatment, Imaging and Metastasis Management
This community focuses on the clinical management of uveal melanoma, the most common primary intraocular cancer in adults, encompassing its diagnosis, local control, and treatment of liver metastases.
The research centers on plaque brachytherapy using isotopes such as ruthenium-106 and iodine-125, alongside proton beam therapy and photodynamic therapy for local tumor control. A significant portion of the work addresses the management of metastatic disease, particularly hepatic perfusion with melphalan and systemic immunotherapies like tebentafusp. Diagnostic and monitoring methods include optical coherence tomography, magnetic resonance imaging, and ultrasound. The community also covers the evaluation of ocular complications following radiotherapy and the molecular biology of choroidal melanoma, including resistance mechanisms and prognostic factors.
The largest share of the community's output is found in radium research, accounting for 2.3% of all radium research, with 392 papers here. Ruthenium research contributes 281 papers, representing 0.4% of that element's research, while iodine research includes 275 papers, or 0.2% of its total.
The community comprises 3,809 papers, published primarily in the British Journal of Ophthalmology, the International Journal of Radiation Oncology Biology Physics, and Radiology.
Recent work includes the CHOPIN trial combining hepatic perfusion with immunotherapy, the development of a novel staging model for uveal melanoma, and the application of machine learning to predict local recurrence after brachytherapy.